G1 Therapeutics Stock
€3.60
Your prediction
G1 Therapeutics Stock
G1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Pros and Cons of G1 Therapeutics in the next few years
Pros
Cons
Performance of G1 Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| G1 Therapeutics | -6.500% | -5.852% | -5.407% | 49.544% | 31.055% | -80.418% | - |
| Ardelyx Inc. | -2.390% | -2.578% | -17.883% | 40.048% | 2.007% | -13.927% | - |
| Salarius Pharmaceuticals Inc. | -3.170% | -2.727% | -46.500% | -69.209% | -22.883% | -98.244% | -99.994% |
| Brainstorm Cell | 1.170% | 3.754% | -21.032% | -81.975% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.G1 Therapeutics (GTHX) appears to be a growth-oriented biotechnology company, which can be observed from a detailed analysis of their financial position. Their financial statements indicate significant investments in research and development, which is expected in this industry. However, a closer look at their balance sheet, cash flow statements, and income statements reveal a mixed picture of both potential promise and some areas of concern.
In conclusion, G1 Therapeutics (GTHX) exhibits a mixed portrait of growth potential and financial concerns. The company has shown a consistent increase in revenue and has aggressively invested in research and development, which is crucial in the biotechnology and medical research industry. Additionally, its strong cash position and a decrease in long-term debt signal a healthy financial stance. However, the negative net income, decline in cash reserves, a rise in operating expenses, and negative free cash flow expose areas of concern that need to be addressed. Investors interested in GTHX should carefully weigh these pros and cons and closely monitor the company's progress and financial performance in the future.
Comments
